Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17121553 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G | December 2020 | July 2023 | Allow | 31 | 1 | 0 | No | No |
| 17119035 | METHODS OF TREATING ACID SPHINGOMYELINASE DEFICIENCY | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17119075 | APOAEQUORIN AND VITAMIN D-CONTAINING COMPOSITIONS AND METHODS OF USING SAME | December 2020 | April 2024 | Allow | 40 | 4 | 0 | Yes | No |
| 17116104 | PREPARATION OF FLAGELLIN VACCINE ADJUVANT-BASED VACCINE TO INDUCE PRODUCTION OF ANTIBODY RECOGNIZING CONFORMATION OF ANTIGENS, AND APPLICATION THEREOF | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17113711 | Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy | December 2020 | April 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17110512 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | December 2020 | May 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17065246 | ANTI-SEMAPHORIN 3A ANTIBODY AND TREATMENT OF ALZHEIMER'S DISEASE AND INFLAMMATORY IMMUNE DISEASES USING SAME | October 2020 | April 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17060541 | DOSING REGIMENS OF PKC ACTIVATORS | October 2020 | July 2023 | Allow | 33 | 2 | 0 | No | No |
| 17034883 | CARDIAC NEURAL CREST CELLS AND METHODS OF USE THEREOF | September 2020 | April 2023 | Abandon | 30 | 0 | 1 | No | No |
| 15733660 | ANTIBODY-BASED METHODS OF DETECTING AND TREATING ALZHEIMER'S DISEASE | September 2020 | November 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17018954 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS | September 2020 | November 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16993914 | Ameliorating Nervous Systems Disorders | August 2020 | September 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16986802 | Materials and Methods for Treatment of Inflammation | August 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16963897 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL CORD INJURY | July 2020 | August 2024 | Abandon | 48 | 1 | 0 | No | No |
| 16933792 | TAU IMMUNOTHERAPY | July 2020 | June 2022 | Allow | 23 | 1 | 0 | No | No |
| 16921223 | NOVEL THERAPEUTIC USES OF MU-OPIATE RECEPTOR PEPTIDES | July 2020 | December 2022 | Abandon | 30 | 2 | 0 | No | No |
| 16909896 | COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING NEUROINFLAMMATION, NEURODEGENERATION, NEUROPATHIC PAIN, AND MIGRAINE | June 2020 | June 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16956339 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES | June 2020 | September 2023 | Allow | 39 | 3 | 1 | No | No |
| 16902829 | DIAGNOSTIC BIOMARKER PROFILES FOR THE DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE | June 2020 | February 2022 | Abandon | 20 | 1 | 1 | No | No |
| 16891841 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | June 2020 | November 2022 | Allow | 29 | 2 | 1 | No | No |
| 16890739 | BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS | June 2020 | August 2023 | Abandon | 38 | 4 | 0 | Yes | No |
| 16890943 | BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION | June 2020 | February 2024 | Allow | 44 | 4 | 1 | No | No |
| 16884980 | ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF | May 2020 | November 2021 | Allow | 18 | 1 | 1 | No | No |
| 16881863 | METHODS FOR TREATING SYSTEMIC SCLEROSIS | May 2020 | July 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16763794 | PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOF | May 2020 | January 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 15931081 | METHODS AND COMPOSITIONS FOR REDUCING GROWTH, MIGRATION AND INVASIVENESS OF BRAIN CANCER STEM CELLS AND IMPROVING SURVIVAL OF PATIENTS WITH BRAIN TUMORS | May 2020 | February 2022 | Allow | 21 | 1 | 1 | No | No |
| 16872064 | DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES | May 2020 | May 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16761935 | NOVEL HUMAN INDUCED PLURIPOTENT STEM CELL LINES FOR MODELING ALZHEIMER'S DISEASE AND USAGE THEREOF | May 2020 | April 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16761827 | IMMUNE RESPONSE PROFILING OF TUMOR-DERIVED EXOSOMES FOR CANCER DIAGNOSIS | May 2020 | October 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16864439 | ANTIBODIES TO AMYLOID BETA | May 2020 | November 2021 | Allow | 19 | 1 | 0 | No | No |
| 16860319 | COMPOSITIONS AND METHODS FOR TREATMENT OF GCASE RELATED DISEASE STATES | April 2020 | October 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16759431 | PODOPLANIN POSITIVE MACROPHAGES | April 2020 | August 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16838993 | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS | April 2020 | March 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16652804 | ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES | April 2020 | December 2021 | Allow | 20 | 1 | 1 | No | No |
| 16649247 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF NEURODEGENERATIVE AND NEUROINFLAMMATORY PATHOLOGIES | March 2020 | February 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 16808458 | COMPOSITION AND METHOD FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS | March 2020 | April 2023 | Abandon | 37 | 3 | 0 | Yes | No |
| 16807902 | Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis | March 2020 | March 2023 | Allow | 37 | 4 | 1 | Yes | No |
| 16799548 | Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury | February 2020 | October 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16795675 | METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY | February 2020 | November 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16639678 | Detection of Fumarate Ester-Derived Modification in a Test Sample | February 2020 | September 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16639125 | TUMOR BLOOD MARKER, USE THEREOF, AND KIT COMPRISING THE SAME | February 2020 | November 2023 | Allow | 45 | 3 | 1 | Yes | No |
| 16639139 | INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE | February 2020 | September 2021 | Allow | 19 | 1 | 1 | No | No |
| 16789319 | ANTI-TRANSTHYRETIN ANTIBODIES | February 2020 | October 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16632483 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | January 2020 | September 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16631991 | METHODS FOR TREATMENT OR PREVENTION OF A NEUROLOGICAL IMMUNITY DISORDER | January 2020 | December 2021 | Allow | 23 | 2 | 0 | No | No |
| 16744404 | HUMANIZED ANTIBODIES | January 2020 | February 2021 | Allow | 13 | 0 | 0 | Yes | No |
| 16740077 | TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF | January 2020 | October 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16628075 | COMPOSITIONS AND METHODS FOR A UNIVERSAL CLINICAL TEST FOR OLFACTORY DYSFUNCTION | January 2020 | August 2023 | Abandon | 44 | 0 | 1 | No | No |
| 16624777 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISM | December 2019 | January 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16616051 | BIOMARKER LEVELS AND NEUROIMAGING FOR DETECTING, MONITORING AND TREATING BRAIN INJURY OR TRAUMA | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16689523 | MUTANT HUNTINGTIN-MEDIATED PROTEIN DYSFUNCTION | November 2019 | February 2022 | Allow | 27 | 2 | 1 | No | No |
| 16688425 | METHODS OF MAINTAINING, EXPANDING, AND DIFFERENTIATING NEURONAL SUBTYPE SPECIFIC PROGENITORS | November 2019 | December 2021 | Allow | 25 | 2 | 1 | Yes | No |
| 16613264 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | November 2019 | October 2023 | Allow | 47 | 3 | 1 | Yes | No |
| 16612529 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16671595 | Methods For The Treatment Of Neurodegeneration | November 2019 | January 2022 | Allow | 27 | 2 | 0 | No | No |
| 16609885 | Monoclonal Antibodies Against Alpha-Synuclein Fibrils | October 2019 | September 2021 | Allow | 22 | 1 | 1 | No | No |
| 16670880 | BIOMARKERS AND METHODS OF USE FOR RADIATION-INDUCED LUNG INJURY | October 2019 | March 2023 | Allow | 41 | 2 | 1 | No | No |
| 16605753 | METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS | October 2019 | February 2024 | Allow | 52 | 4 | 1 | Yes | No |
| 16597400 | RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE | October 2019 | April 2021 | Allow | 19 | 2 | 0 | No | No |
| 16596258 | EARLY STAGE PARKINSON'S DISEASE DIAGNOSTIC KITS AND METHODS | October 2019 | September 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16603466 | POLYPEPTIDE-ANTIBODY COMPLEXES AND USES THEREOF | October 2019 | August 2022 | Allow | 34 | 1 | 0 | No | No |
| 16500289 | Synthetic Particle Antibody Compositions And Uses Thereof | October 2019 | May 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16588054 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR | September 2019 | May 2021 | Allow | 19 | 2 | 1 | No | No |
| 16582742 | Diagnosis of a neuroautoimmune disease | September 2019 | February 2021 | Allow | 17 | 2 | 1 | Yes | No |
| 16493657 | IDENTIFICATION OF SIGNATURES FOR NEURODEGENERATION DISEASES DIAGNOSES | September 2019 | December 2020 | Abandon | 15 | 0 | 1 | No | No |
| 16489778 | PREVENTIVE OR THERAPEUTIC AGENT FOR HTLV-1 ASSOCIATED MYELOPATHY USING LOW-DOSE OF ANTI-CCR4 ANTIBODY | August 2019 | March 2021 | Allow | 19 | 2 | 0 | No | No |
| 16547695 | DETECTION AND QUANTIFICATION OF RAS-RAF-MAPK PATHWAY PROTEINS | August 2019 | June 2024 | Abandon | 58 | 4 | 1 | Yes | No |
| 16487720 | COMPOUND AND METHOD OF MEASURING INTESTINAL PERMEABILITY AND LEAKY GUT | August 2019 | January 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16543854 | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders | August 2019 | December 2020 | Abandon | 16 | 1 | 0 | No | No |
| 16486238 | ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF | August 2019 | June 2020 | Allow | 10 | 0 | 0 | Yes | No |
| 16486286 | NON-INVASIVE BRAIN INJURY DIAGNOSTIC DEVICE | August 2019 | July 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16482160 | METHOD FOR CONTROLLING DIFFERENTIATION OF PLURIPOTENT STEM CELLS | July 2019 | November 2022 | Allow | 39 | 2 | 1 | No | No |
| 16481013 | METHOD FOR DETECTING CONSTITUENT COMPONENT OF ANTIBODY-DRUG CONJUGATE | July 2019 | November 2022 | Allow | 40 | 2 | 1 | No | No |
| 16514701 | METHODS TO ENHANCE NERVE REGENERATION UTILIZING NEURAL STEM CELLS AND IL12P40 | July 2019 | January 2021 | Abandon | 18 | 1 | 1 | No | No |
| 16513058 | DOSING REGIMENS OF PKC ACTIVATORS | July 2019 | July 2021 | Allow | 24 | 3 | 0 | Yes | No |
| 16477391 | GAMMA-SECRETASE STABILIZING COMPOUND SCREENING ASSAY | July 2019 | January 2022 | Allow | 30 | 4 | 1 | No | No |
| 16507586 | METHOD OF CREATING HUMAN PLURIPOTENT STEM CELL DERIVED BRAIN PERICYTE-LIKE CELLS | July 2019 | December 2022 | Allow | 41 | 1 | 1 | No | No |
| 16507437 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | July 2019 | March 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16505534 | DETECTION AND TREATMENT OF NEUROLOGICAL DISEASES | July 2019 | February 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16474662 | METHOD FOR PRODUCING PLURIPOTENT STEM CELL-DERIVED SPHERICAL NEURAL MASS HAVING SUPPRESSED TERATOMA FORMATION | June 2019 | December 2023 | Allow | 54 | 3 | 1 | Yes | No |
| 16474170 | DETECTION METHOD FOR CHROMOSOMAL ABNORMALITIES AND METHOD FOR EVALUATING INDUCIBILITY | June 2019 | October 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16473482 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | June 2019 | May 2021 | Allow | 22 | 2 | 1 | No | No |
| 16449547 | MATERIALS AND METHODS FOR TREATMENT OF INFLAMMATION | June 2019 | September 2020 | Abandon | 15 | 2 | 0 | No | No |
| 16449096 | NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS | June 2019 | August 2021 | Allow | 26 | 2 | 0 | Yes | No |
| 16468960 | ANTIBODY VARIANTS TRANSMIGRATING THE BLOOD-BRAIN BARRIER AND USES THEREOF | June 2019 | May 2020 | Allow | 11 | 0 | 0 | No | No |
| 16467750 | NEURONAL SURVIVAL AND AXONAL REGENERATION THROUGH INCREASING MITOCHONDRIAL MOTILITY | June 2019 | April 2022 | Allow | 34 | 2 | 1 | Yes | Yes |
| 16426795 | Basal Ganglia-On-Chip For Screening Therapeutic Agents For Brain And Nervous System Diseases | May 2019 | February 2024 | Allow | 57 | 3 | 1 | Yes | No |
| 16464517 | NEW BIOMARKERS OF HUMAN SKIN AGING | May 2019 | May 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16421152 | METHODS FOR EVALUATION OF TREATMENT AND PROGRESSION OF NEUROLOGICAL DISORDERS | May 2019 | May 2021 | Abandon | 24 | 2 | 1 | No | No |
| 16346841 | INFRARED ASSAY DETECTING SECONDARY STRUCTURE PROFILES OF ALPHA-SYNUCLEIN | May 2019 | September 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16345562 | ANTIBODIES TO UBIQUITIN C-TERMINAL HYDROLASE L1 (UCH-L1) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND RELATED METHODS | April 2019 | March 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16342504 | Neuronal and Oligodendrocyte Survival Modulation | April 2019 | September 2020 | Abandon | 17 | 1 | 0 | No | No |
| 16340026 | DETECTION OF CD-155, THE POLIOVIRUS RECEPTOR | April 2019 | July 2022 | Allow | 39 | 2 | 0 | No | No |
| 16338654 | GENETIC SUSCEPTIBILITY DIAGNOSIS AND TREATMENT OF MENTAL DISORDERS | April 2019 | July 2020 | Abandon | 16 | 0 | 1 | No | No |
| 16336016 | APOAEQUORIN AND VITAMIN D-CONTAINING COMPOSITIONS AND METHODS OF USING SAME | March 2019 | December 2020 | Abandon | 21 | 1 | 1 | No | No |
| 16355661 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | March 2019 | September 2020 | Abandon | 19 | 1 | 1 | No | No |
| 16333979 | BIOMARKERS FOR USE IN DETERMINING RESPONSE TO TREATMENT OF NEURODEGENERATION DISEASE | March 2019 | December 2020 | Abandon | 21 | 2 | 0 | No | No |
| 16331063 | Bi-Functional Anti-Tau Polypeptides and Use Thereof | March 2019 | February 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16293134 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS | March 2019 | June 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16283530 | CHIMERIC ANTIGEN RECEPTORS HAVING GITR INTRACELLULAR DOMAIN AS CO-STIMULATORY DOMAIN | February 2019 | January 2022 | Allow | 35 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MACFARLANE, STACEY NEE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MACFARLANE, STACEY NEE works in Art Unit 1649 and has examined 690 patent applications in our dataset. With an allowance rate of 40.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner MACFARLANE, STACEY NEE's allowance rate of 40.6% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MACFARLANE, STACEY NEE receive 2.18 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MACFARLANE, STACEY NEE is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +47.9% benefit to allowance rate for applications examined by MACFARLANE, STACEY NEE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.4% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 91.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 101.6% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.9% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.